Ketorolac for Patients Undergoing Implant-Based Breast Reconstruction: Impact on Hospital Length of Stay and Postoperative Narcotic Use.
Opioid drugs have been a mainstay medication for the management of postoperative pain for several decades, however in recent years there has been a push towards investigating alternative treatment options. While ketorolac has been widely used by other medical and surgical specialties for analgesia, its use in plastic surgery has been widely debated. The purpose of our study is to investigate the efficacy of ketorolac as an adjunct in postoperative pain management. We performed a retrospective review of patients undergoing implant-based breast reconstruction after mastectomy between January 2012 and December 2016. Other risk factors, such as chronic anticoagulation, aspirin, or coagulopathies, were documented as well. There were 198 patients who met our inclusion criteria. Our results demonstrated that patients who received ketorolac used significantly less narcotics than patients who did not, 80 mg vs 108.8 mg (P = 0.002). The results showed that patients who received ketorolac had a decreased length of hospitalization, 1.9 days vs 2.1 days (P = 0.04). Generous narcotic prescribing has received greater scrutiny in recent years. Aside from the risk of increased narcotic availability in the community, the side effects of nausea, puritis, and constipation delay patient recovery. Our data shows that patients who received ketorolac have a decreased length of hospital stay and lower narcotic use, suggesting ketorolac may be a safe and cost effective adjust to a multi-modal pain control regimen postoperatively.